{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T13:23:39Z","timestamp":1709472219945},"posted":{"date-parts":[[2023,5,3]]},"group-title":"In Review","reference-count":68,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>High grade serous ovarian carcinoma (HGSOC) accounts for ~\u200970% of ovarian cancer cases. Non-invasive, highly specific blood-based tests for pre-symptomatic screening in women are crucial to reducing the mortality associated with this disease. Since most HGSOCs typically arise from the fallopian tubes (FT), our biomarker search focused on proteins found on the surface of extracellular vesicles (EVs) released by both FT and HGSOC tissue explants and representative cell lines. Using mass spectrometry, 985 EV proteins (exo-proteins) were identified that comprised the FT\/HGSOC EV core proteome. Transmembrane exo-proteins were prioritized because these could serve as antigens for capture and\/or detection. With a nano-engineered microfluidic platform, six newly discovered exo-proteins (ACSL4, IGSF8, ITGA2, ITGA5, ITGB3, MYOF) plus a known HGSOC associated protein, FOLR1 exhibited classification performance ranging from 85\u201398% in a case-control study using plasma samples representative of early (including stage IA\/B) and late stage (stage III) HGSOCs. Furthermore, by linear combination of IGSF8 and ITGA5 based on logistic regression analysis, we achieved a sensitivity of 80% (99.8% specificity). These lineage-associated exo-biomarkers have potential to detect cancer while localized to the FT when patient outcomes are more favorable.<\/jats:p>","DOI":"10.21203\/rs.3.rs-2814022\/v1","type":"posted-content","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T14:00:13Z","timestamp":1683208813000},"source":"Crossref","is-referenced-by-count":1,"title":["Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer"],"prefix":"10.21203","author":[{"given":"Camille","family":"Trinidad","sequence":"first","affiliation":[{"name":"The University of Kansas Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Pathak","sequence":"additional","affiliation":[{"name":"The University of Kansas Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Cheng","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Cheng","family":"Tzeng","sequence":"additional","affiliation":[{"name":"The Donald Danforth Plant Science Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashna","family":"Madan","sequence":"additional","affiliation":[{"name":"The University of Kansas Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Sardiu","sequence":"additional","affiliation":[{"name":"The University of Kansas Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Bantis","sequence":"additional","affiliation":[{"name":"The University of Kansas Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clayton","family":"Deighan","sequence":"additional","affiliation":[{"name":"NanoFCM"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Jewell","sequence":"additional","affiliation":[{"name":"The University of Kansas Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Godwin","sequence":"additional","affiliation":[{"name":"The University of Kansas Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/17520363.2.3.291","article-title":"Jr. Early detection of ovarian cancer","volume":"2","author":"Das PM","year":"2008","unstructured":"Das, P. M. & Bast, R. C., Jr. Early detection of ovarian cancer. Biomark Med 2, 291\u2013303, doi:10.2217\/17520363.2.3.291 (2008).","journal-title":"Biomark Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1158\/1940-6207.CAPR-11-0468","article-title":"Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening","volume":"5","author":"Drescher CW","year":"2012","unstructured":"Drescher, C. W. et al. Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila) 5, 1015\u20131024, doi:10.1158\/1940-6207.CAPR-11-0468 (2012).","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/1097-0142(19951115)76:10+<2086::AID-CNCR2820761330>3.0.CO;2-L","article-title":"Ovarian cancer screening","volume":"76","author":"Nagell JR","year":"1995","unstructured":"van Nagell, J. R., Jr., Gallion, H. H., Pavlik, E. J. & DePriest, P. D. Ovarian cancer screening. Cancer 76, 2086\u20132091 (1995).","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel RL","year":"2015","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J Clin 65, 5\u201329, doi:10.3322\/caac.21254 (2015).","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell DD","year":"2010","unstructured":"Bowtell, D. D. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10, 803\u2013808, doi:10.1038\/nrc2946 (2010).","journal-title":"Nat Rev Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac D","year":"2011","unstructured":"Jelovac, D. & Armstrong, D. K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61, 183\u2013203, doi:10.3322\/caac.20113 (2011).","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2013shifting the paradigm","volume":"42","author":"Kurman RJ","year":"2011","unstructured":"Kurman, R. J. & Shih Ie, M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2013shifting the paradigm. Hum Pathol 42, 918\u2013931, doi:10.1016\/j.humpath.2011.03.003 (2011).","journal-title":"Hum Pathol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2007\/309382","article-title":"Jr. Early detection of ovarian cancer","volume":"23","author":"Badgwell D","year":"2007","unstructured":"Badgwell, D. & Bast, R. C., Jr. Early detection of ovarian cancer. Dis Markers 23, 397\u2013410 (2007).","journal-title":"Dis Markers"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jcb.240590926","article-title":"Prospective on ovarian cancer: why prevent?","volume":"23","author":"Hoskins WJ","year":"1995","unstructured":"Hoskins, W. J. Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl 23, 189\u2013199 (1995).","journal-title":"J Cell Biochem Suppl"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1002\/cncr.28183","article-title":"A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value","volume":"119","author":"Lu KH","year":"2013","unstructured":"Lu, K. H. et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119, 3454\u20133461, doi:10.1002\/cncr.28183 (2013).","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/475983","author":"Rein BJ","year":"2011","unstructured":"Rein, B. J. et al. Potential markers for detection and monitoring of ovarian cancer. J Oncol 2011, 475983, doi:10.1155\/2011\/475983 (2011)."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-540-37696-5_9","article-title":"Prevention and early detection of ovarian cancer: mission impossible?","volume":"174","author":"Bast RC","year":"2007","unstructured":"Bast, R. C., Jr. et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 174, 91\u2013100 (2007).","journal-title":"Recent Results Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","article-title":"Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers","volume":"76","author":"Skates SJ","year":"1995","unstructured":"Skates, S. J. et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76, 2004\u20132010 (1995).","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S1470-2045(07)70357-1","article-title":"Benign causes of increased serum CA-125 concentration","volume":"8","author":"Sevinc A","year":"2007","unstructured":"Sevinc, A., Adli, M., Kalender, M. E. & Camci, C. Benign causes of increased serum CA-125 concentration. Lancet Oncol 8, 1054\u20131055, doi:10.1016\/S1470-2045(07)70357-1 (2007).","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1006\/gyno.2001.6575","article-title":"Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study","volume":"85","author":"Topalak O","year":"2002","unstructured":"Topalak, O. et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 85, 108\u2013113, doi:10.1006\/gyno.2001.6575 (2002).","journal-title":"Gynecol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs IJ","year":"2016","unstructured":"Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945\u2013956, doi:10.1016\/S0140-6736(15)01224-6 (2016).","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon U","year":"2021","unstructured":"Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 397, 2182\u20132193, doi:10.1016\/S0140-6736(21)00731-5 (2021).","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy SI","year":"2017","unstructured":"Labidi-Galy, S. I. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8, 1093, doi:10.1038\/s41467-017-00962-1 (2017).","journal-title":"Nat Commun"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets R","year":"2013","unstructured":"Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751\u2013765, doi:10.1016\/j.ccr.2013.10.013 (2013).","journal-title":"Cancer Cell"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee Y","year":"2007","unstructured":"Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211, 26\u201335, doi:10.1002\/path.2091 (2007).","journal-title":"J Pathol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"Wu RC","year":"2019","unstructured":"Wu, R. C. et al. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. J Pathol 248, 41\u201350, doi:10.1002\/path.5219 (2019).","journal-title":"J Pathol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/sajc.sajc_187_17","article-title":"Prophylactic salpingectomy and ovarian cancer: An evidence-based analysis","volume":"7","author":"Anggraeni TD","year":"2018","unstructured":"Anggraeni, T. D., Al Fattah, A. N. & Surya, R. Prophylactic salpingectomy and ovarian cancer: An evidence-based analysis. South Asian J Cancer 7, 42\u201345, doi:10.4103\/sajc.sajc_187_17 (2018).","journal-title":"South Asian J Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2015.12.003","article-title":"Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis","volume":"55","author":"Yoon SH","year":"2016","unstructured":"Yoon, S. H., Kim, S. N., Shim, S. H., Kang, S. B. & Lee, S. J. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis. Eur J Cancer 55, 38\u201346, doi:10.1016\/j.ejca.2015.12.003 (2016).","journal-title":"Eur J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino A","year":"2015","unstructured":"Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329\u2013335, doi:10.1038\/nature15756 (2015).","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles","volume":"30","author":"Colombo M","year":"2014","unstructured":"Colombo, M., Raposo, G. & Thery, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30, 255\u2013289, doi:10.1146\/annurev-cellbio-101512-122326 (2014).","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Yanez-Mo M","year":"2015","unstructured":"Yanez-Mo, M. et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 4, 27066, doi:10.3402\/jev.v4.27066 (2015).","journal-title":"J Extracell Vesicles"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.009","author":"Hoshino A","year":"2020","unstructured":"Hoshino, A. et al. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell 182, 1044\u20131061 e1018, doi:10.1016\/j.cell.2020.07.009 (2020)."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1039\/c4lc00662c","article-title":"Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology","volume":"14","author":"He M","year":"2014","unstructured":"He, M., Crow, J., Roth, M., Zeng, Y. & Godwin, A. K. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip 14, 3773\u20133780, doi:10.1039\/c4lc00662c (2014).","journal-title":"Lab Chip"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1039\/c5lc01117e","article-title":"A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis","volume":"16","author":"Zhao Z","year":"2016","unstructured":"Zhao, Z., Yang, Y., Zeng, Y. & He, M. A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. Lab Chip 16, 489\u2013496, doi:10.1039\/c5lc01117e (2016).","journal-title":"Lab Chip"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0356-9","article-title":"Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip","author":"Zhang P","year":"2019","unstructured":"Zhang, P. et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nature Biomedical Engineering, doi:https:\/\/doi.org\/10.1038\/s41551-019-0356-9 (2019).","journal-title":"Nature Biomedical Engineering"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nbt.2886","article-title":"Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor","volume":"32","author":"Im H","year":"2014","unstructured":"Im, H. et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol 32, 490\u2013495, doi:10.1038\/nbt.2886 (2014).","journal-title":"Nat Biotechnol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1039\/c9sc00961b","article-title":"Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer","volume":"10","author":"Zhang P","year":"2019","unstructured":"Zhang, P., Zhou, X. & Zeng, Y. Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer. Chem Sci 10, 5495\u20135504, doi:10.1039\/c9sc00961b (2019).","journal-title":"Chem Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41596-020-00466-1","article-title":"Isolation and characterization of extracellular vesicle subpopulations from tissues","volume":"16","author":"Crescitelli R","year":"2021","unstructured":"Crescitelli, R., Lasser, C. & Lotvall, J. Isolation and characterization of extracellular vesicle subpopulations from tissues. Nat Protoc 16, 1548\u20131580, doi:10.1038\/s41596-020-00466-1 (2021).","journal-title":"Nat Protoc"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1722433","DOI":"10.1080\/20013078.2020.1722433","article-title":"Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation","volume":"9","author":"Crescitelli R","year":"2020","unstructured":"Crescitelli, R. et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation. J Extracell Vesicles 9, 1722433, doi:10.1080\/20013078.2020.1722433 (2020).","journal-title":"J Extracell Vesicles"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Thery C","year":"2018","unstructured":"Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7, 1535750, doi:10.1080\/20013078.2018.1535750 (2018).","journal-title":"J Extracell Vesicles"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"13012","DOI":"10.1038\/s41598-019-49671-3","article-title":"3D cell culture stimulates the secretion of in vivo like extracellular vesicles","volume":"9","author":"Thippabhotla S","year":"2019","unstructured":"Thippabhotla, S., Zhong, C. & He, M. 3D cell culture stimulates the secretion of in vivo like extracellular vesicles. Sci Rep 9, 13012, doi:10.1038\/s41598-019-49671-3 (2019).","journal-title":"Sci Rep"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1476-4598-13-134","article-title":"RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy","volume":"13","author":"Tominaga N","year":"2014","unstructured":"Tominaga, N. et al. RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. Mol Cancer 13, 134, doi:10.1186\/1476-4598-13-134 (2014).","journal-title":"Mol Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41556-021-00693-y","article-title":"Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker","volume":"23","author":"Kugeratski FG","year":"2021","unstructured":"Kugeratski, F. G. et al. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat Cell Biol 23, 631\u2013641, doi:10.1038\/s41556-021-00693-y (2021).","journal-title":"Nat Cell Biol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1136\/bmj.306.6884.1030","article-title":"Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography","volume":"306","author":"Jacobs I","year":"1993","unstructured":"Jacobs, I. et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306, 1030\u20131034, doi:10.1136\/bmj.306.6884.1030 (1993).","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore RG","year":"2009","unstructured":"Moore, R. G. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112, 40\u201346, doi:10.1016\/j.ygyno.2008.08.031 (2009).","journal-title":"Gynecol Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1097\/AOG.0b013e31821b1d80","article-title":"Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay","volume":"117","author":"Miller RW","year":"2011","unstructured":"Miller, R. W. et al. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 117, 1298\u20131306, doi:10.1097\/AOG.0b013e31821b1d80 (2011).","journal-title":"Obstet Gynecol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/sim.8869","article-title":"The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves","volume":"40","author":"Bantis LE","year":"2021","unstructured":"Bantis, L. E. et al. The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves. Stat Med 40, 1767\u20131789, doi:10.1002\/sim.8869 (2021).","journal-title":"Stat Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","article-title":"Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance","volume":"25","author":"Seguin L","year":"2015","unstructured":"Seguin, L., Desgrosellier, J. S., Weis, S. M. & Cheresh, D. A. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 25, 234\u2013240, doi:10.1016\/j.tcb.2014.12.006 (2015).","journal-title":"Trends Cell Biol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1541-7786.MCR-16-0058","article-title":"Exosome-mediated Transfer of alphavbeta3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype","volume":"14","author":"Singh A","year":"2016","unstructured":"Singh, A. et al. Exosome-mediated Transfer of alphavbeta3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res 14, 1136\u20131146, doi:10.1158\/1541-7786.MCR-16-0058 (2016).","journal-title":"Mol Cancer Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e12140","DOI":"10.1002\/jev2.12140","article-title":"Formation of a protein corona on the surface of extracellular vesicles in blood plasma","volume":"10","author":"Toth EA","year":"2021","unstructured":"Toth, E. A. et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J Extracell Vesicles 10, e12140, doi:10.1002\/jev2.12140 (2021).","journal-title":"J Extracell Vesicles"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli KR","year":"2008","unstructured":"Kalli, K. R. et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108, 619\u2013626, doi:10.1016\/j.ygyno.2007.11.020 (2008).","journal-title":"Gynecol Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13048-018-0387-y","article-title":"FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells","volume":"11","author":"Huang MJ","year":"2018","unstructured":"Huang, M. J. et al. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells. J Ovarian Res 11, 15, doi:10.1186\/s13048-018-0387-y (2018).","journal-title":"J Ovarian Res"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41551-019-0356-9","article-title":"Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip","volume":"3","author":"Zhang P","year":"2019","unstructured":"Zhang, P. et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat Biomed Eng 3, 438\u2013451, doi:10.1038\/s41551-019-0356-9 (2019).","journal-title":"Nat Biomed Eng"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jprot.2012.12.029","article-title":"Characterization and proteomic analysis of ovarian cancer-derived exosomes","volume":"80","author":"Liang B","year":"2013","unstructured":"Liang, B. et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteomics 80, 171\u2013182, doi:10.1016\/j.jprot.2012.12.029 (2013).","journal-title":"J Proteomics"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1158\/0008-5472.CAN-18-3538","article-title":"A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer","volume":"79","author":"Dorayappan KDP","year":"2019","unstructured":"Dorayappan, K. D. P. et al. A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer. Cancer Res 79, 3503\u20133513, doi:10.1158\/0008-5472.CAN-18-3538 (2019).","journal-title":"Cancer Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.03.003","author":"Zaborowski MP","year":"2019","unstructured":"Zaborowski, M. P. et al. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Rep 27, 255\u2013268 e256, doi:10.1016\/j.celrep.2019.03.003 (2019)."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2020_200707N705","author":"Ma LL","year":"2021","unstructured":"Ma, L. L., Liang, L., Zhou, D. & Wang, S. W. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4. Neoplasma 68, 165\u2013173, doi:10.4149\/neo_2020_200707N705 (2021)."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","article-title":"Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target","volume":"68","author":"Sawada K","year":"2008","unstructured":"Sawada, K. et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68, 2329\u20132339, doi:10.1158\/0008-5472.CAN-07-5167 (2008).","journal-title":"Cancer Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21037\/tcr.2019.02.11","article-title":"STX4 expression is associated with classification, clinical stage and lymphatic metastasis in ovarian cancer","volume":"8","author":"Ye W","year":"2019","unstructured":"Ye, W. et al. STX4 expression is associated with classification, clinical stage and lymphatic metastasis in ovarian cancer. Transl Cancer Res 8, 466\u2013472, doi:10.21037\/tcr.2019.02.11 (2019).","journal-title":"Transl Cancer Res"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"103168","DOI":"10.1016\/j.isci.2021.103168","article-title":"Site-specific N-glycosylation of integrin alpha2 mediates collagen-dependent cell survival","volume":"24","author":"Huang YL","year":"2021","unstructured":"Huang, Y. L. et al. Site-specific N-glycosylation of integrin alpha2 mediates collagen-dependent cell survival. iScience 24, 103168, doi:10.1016\/j.isci.2021.103168 (2021).","journal-title":"iScience"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.18632\/aging.102954","article-title":"Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT\/FoxO1 pathway","volume":"12","author":"Ma L","year":"2020","unstructured":"Ma, L. et al. Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT\/FoxO1 pathway. Aging (Albany NY) 12, 5336\u20135351, doi:10.18632\/aging.102954 (2020).","journal-title":"Aging (Albany NY)"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/1471-2407-9-336","article-title":"External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas","volume":"9","author":"Partheen K","year":"2009","unstructured":"Partheen, K. et al. External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC Cancer 9, 336, doi:10.1186\/1471-2407-9-336 (2009).","journal-title":"BMC Cancer"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1084\/jem.20180765","article-title":"Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer","volume":"216","author":"Gao Q","year":"2019","unstructured":"Gao, Q. et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med 216, 688\u2013703, doi:10.1084\/jem.20180765 (2019).","journal-title":"J Exp Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"83669","DOI":"10.18632\/oncotarget.13276","article-title":"Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes","volume":"7","author":"Blomme A","year":"2016","unstructured":"Blomme, A. et al. Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes. Oncotarget 7, 83669\u201383683, doi:10.18632\/oncotarget.13276 (2016).","journal-title":"Oncotarget"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/14796694.2.6.733","article-title":"Multiple biomarker panels for early detection of ovarian cancer","volume":"2","author":"Yurkovetsky ZR","year":"2006","unstructured":"Yurkovetsky, Z. R., Linkov, F. Y., D, E. M. & Lokshin, A. E. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol 2, 733\u2013741, doi:10.2217\/14796694.2.6.733 (2006).","journal-title":"Future Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro S","year":"2013","unstructured":"Ferraro, S. et al. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol 66, 273\u2013281, doi:10.1136\/jclinpath-2012-201031 (2013).","journal-title":"J Clin Pathol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1073\/pnas.1017300108","article-title":"Modeling high-grade serous ovarian carcinogenesis from the fallopian tube","volume":"108","author":"Karst AM","year":"2011","unstructured":"Karst, A. M., Levanon, K. & Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 108, 7547\u20137552, doi:10.1073\/pnas.1017300108 (2011).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jcp.48.9.876","article-title":"A \"quickscore\" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas","volume":"48","author":"Detre S","year":"1995","unstructured":"Detre, S., Saclani Jotti, G. & Dowsett, M. A \"quickscore\" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48, 876\u2013878, doi:10.1136\/jcp.48.9.876 (1995).","journal-title":"J Clin Pathol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/bioinformatics\/btw624","article-title":"The START App: a web-based RNAseq analysis and visualization resource","volume":"33","author":"Nelson JW","year":"2017","unstructured":"Nelson, J. W., Sklenar, J., Barnes, A. P. & Minnier, J. The START App: a web-based RNAseq analysis and visualization resource. Bioinformatics 33, 447\u2013449, doi:10.1093\/bioinformatics\/btw624 (2017).","journal-title":"Bioinformatics"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jprot.2015.07.036","article-title":"QPROT: Statistical method for testing differential expression using protein-level intensity data in label-free quantitative proteomics","volume":"129","author":"Choi H","year":"2015","unstructured":"Choi, H., Kim, S., Fermin, D., Tsou, C. C. & Nesvizhskii, A. I. QPROT: Statistical method for testing differential expression using protein-level intensity data in label-free quantitative proteomics. J Proteomics 129, 121\u2013126, doi:10.1016\/j.jprot.2015.07.036 (2015).","journal-title":"J Proteomics"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705","article-title":"A New Look at the Statistical Model Identification","volume":"19","author":"Akaike H","year":"1974","unstructured":"Akaike, H. A New Look at the Statistical Model Identification. IEEE Transactions on Automatic Control 19, doi:10.1109\/TAC.1974.1100705 (1974).","journal-title":"IEEE Transactions on Automatic Control"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden WJ","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335, doi:10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 (1950).","journal-title":"Cancer"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"D543-D552","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol Y","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res 50, D543-D552, doi:10.1093\/nar\/gkab1038 (2022).","journal-title":"Nucleic Acids Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2814022\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2814022\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:10:43Z","timestamp":1698682243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2814022\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":68,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2814022\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41598-023-44050-5","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,5,3]]},"subtype":"preprint"}}